Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4551 | US Neulasta Wiki | 1.00 |
drug1878 | Hesperidin and Diosmin mixture Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The study was an assessor-blind, balanced, parallel, randomized, two-treatment, comparative immunogenicity study of multiple doses of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6 mL; Qilu Pharmaceutical Co., Ltd. proposed biosimilar QL0605 compared to innovator product, US-Neulasta) in healthy, adult, human subjects.
Description: Incidence (absolute and percentage) of anti-drug antibody by treatment
Measure: Incidence (absolute and percentage) of ADA by treatment Time: 91 daysDescription: Area under the concentration-time curve (AUC) from time zero to last quantifiable concentration
Measure: AUC0-t Time: 91 daysDescription: Area under the concentration-time curve (AUC) from time zero to infinity
Measure: AUCinf Time: 91 daysDescription: Maximum serum concentration
Measure: Cmax Time: 91 daysDescription: time corresponding to the occurrence of Cmax
Measure: tmax Time: 91 daysDescription: Area under the ANC-time curve (AUC) from time zero to day41
Measure: AUEC(0-Day41) Time: 41 daysDescription: Maximum ANC concentration
Measure: ANC Emax Time: 91 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports